

Cite this: *Chem. Sci.*, 2025, **16**, 2413

All publication charges for this article have been paid for by the Royal Society of Chemistry

Received 12th November 2024  
Accepted 28th December 2024

DOI: 10.1039/d4sc07668k  
[rsc.li/chemical-science](http://rsc.li/chemical-science)

## Introduction

RNA interference was discovered in 1998 but it was only in 2018 that small interfering RNA (siRNA) found clinical applications.<sup>1,2</sup> Since 2018, five siRNA drugs have been approved by the FDA and EMA.<sup>3,4</sup> These success stories rely extensively on the development of effective non-viral delivery systems based on glycoconjugates or lipid nanoparticles (LNP). Further development in this area will contribute to broadening the scope of application of RNA therapeutics.<sup>5,6</sup> In that perspective, cationic polymers<sup>7,8</sup> have received a strong interest but suffer from a limited efficacy, in part due to poor siRNA release.<sup>9</sup> To address this challenge, we have developed pH-sensitive cationic dynamic covalent polymers (DCPs) which spontaneously depolymerize at the acidic pH found in endosomes,<sup>10</sup> and can indeed deliver siRNA in live cells.<sup>11</sup> Furthermore, exploring self-assembly pathways<sup>12</sup> for accessing dynamic vectors,<sup>13,14</sup> we recently evidenced that these DCPs can be formed *in situ* through a siRNA-templated process.<sup>15–17</sup> Such an approach alleviates the process of polyplexes formation and enables more rapid screening of components.<sup>16,18,19</sup> However, the activity of non-functionalized cationic DCPs as siRNA vectors remains hitherto limited to detectable silencing activity in cell culture at

elevated siRNA doses ( $\geq 200$  nM) and high N/P ratio<sup>20</sup> ( $\geq 20$ ).<sup>16,21</sup> An opportunity for improving the activity of cationic polymers and dendrimers as siRNA vectors is to exploit hydrophobization. Hydrophobization can indeed contribute to (i) directing the self-assembly toward monodisperse nanoparticles,<sup>22–24</sup> and (ii) improving cell uptake by stabilizing the interactions with the cell membranes during endocytosis.<sup>25,26</sup> Tuning the balance of electrostatic and hydrophobic interactions at play during cell penetration is a critical challenge in delivery applications to promote cell penetration without damaging the cell membrane.<sup>27,28</sup> Herein, we report the synthesis of amphiphilic peptide-based monomers and show that they undergo a siRNA-templated dynamic covalent polymerization, which results in more defined nanoparticles that are able to deliver siRNA in cells with a greater efficacy than previous generations. This work extends thus the pioneering reports from the Matile and Montenegro groups on, respectively, small molecules<sup>29</sup> and polymer-based<sup>30</sup> dynamic covalent amphiphiles, to dynamic covalent lipopolplexes made of amphiphilic dynamic covalent polymers (Fig. 1).

## Results and discussion

### Design and synthesis

Hydrophobization can be achieved using aromatic amino acids (e.g. tryptophan, Trp), saturated fatty acids or more complex lipids. While introducing Trp was found advantageous in cell-penetrating peptides as revealed by the Sagan/Alves groups<sup>31–33</sup> and others,<sup>34</sup> it unfortunately did not prove superior when applied to our DCPs (data not shown). Then, inspired by the successful use of saturated fatty acids for making cationic and ionizable lipids for siRNA transfection by LNPs,<sup>35,36</sup> we turned our attention to appending our cationic peptide-based building blocks with fatty


<sup>a</sup>Institut des Biomolécules Max Mousseron (IBMM), Université de Montpellier, CNRS, ENSCM, Montpellier, France. E-mail: nadir.bettache@umontpellier.fr; sebastien.ulrich@cnrs.fr

<sup>b</sup>Sorbonne Université, École Normale Supérieure, PSL University, CNRS, Laboratoire des Biomolécules (LBM), Paris, France. E-mail: emmanuelle.sachon@SORBONNE-UNIVERSITE.FR

<sup>c</sup>Université de Bordeaux, CNRS, Inserm, ARNA, UMR 5320, U1212, Bordeaux, France

† Electronic supplementary information (ESI) available: Synthesis and characterization of peptide-based monomers, data of siRNA delivery, and characterization of nanoparticles. See DOI: <https://doi.org/10.1039/d4sc07668k>





**Fig. 1** Delivery of siRNA by dynamic covalent polymers (DCPs) which formation occurs through siRNA templating: previous design of cationic DCPs made by combining bisaldehyde and aminoxy-hydrazide peptides (top), and present work introducing increasing amount of amphiphilic monomers featuring various fatty acid tails ( $n = 6, 10, 12, 18$ ), thereby screening dynamic combinatorial libraries of acylhydrazone-based DCPs with increasing percentage of hydrophobicity as well as increasing fatty acid chain length, and identifying dynamic covalent lipopolplexes (depicted is the system made of 100% amphiphilic monomers) with improved efficacy for siRNA delivery (bottom). Created using BioRender. Garcia Coll J. (2025) <https://BioRender.com/c68l352>.

acids positioned at their N-terminus, screening the effect of chain length and comparing with non-amphiphilic DCPs. Monomers made of three arginines were selected since they were previously found to best promote siRNA complexation and delivery.<sup>16</sup>

The non-amphiphilic cationic bisaldehyde peptide **A** was synthesized as previously described by solid phase peptide synthesis (SPPS). An additional coupling with fatty acids through amide-bond formation was performed directly on solid support at the end of the SPPS and yielded the desired amphiphiles **A-Cn** ( $n = 6, 10, 12, 18$ ) in 3–28% overall yields (Scheme 1).


The complementary bishydrazide peptides **H** and **H-Cn** ( $n = 6, 10, 12, 18$ ) were similarly obtained by SPPS, using a non-natural glutamic acid hydrazide amino acid and a modified 2-chlorotriptyl hydrazine resin (see ESI†), in 2–30% overall yields (Scheme 1). All the amphiphilic peptides were nicely soluble in water up to 10 mM, except the C18 ones which were used for further studies from 10 mM stock solutions in DMSO.

The multi-component screening involves either 3-components, introducing one amphiphilic monomer at a time, or 4-components where both amphiphilic monomers are introduced simultaneously in the same proportion (Scheme 2).


### SiRNA complexation

SiRNA complexation was assessed by an electrophoretic gel retardation assay to identify the optimal monomers


### BisAldehyde Amphiphilic Peptides



### BisHydrazide Amphiphilic Peptides



### Non-amphiphilic Peptides



**Scheme 1** Synthetic route for the preparation of the amphiphilic cationic peptide monomers (bisaldehydes **A-Cn**, top; bishydrazides **H-Cn**, bottom), and non-amphiphilic building blocks **A** and **H**.

composition, testing different N/P ratio. The activity of DCPs formed *in situ* through siRNA-templating was compared with the activity of the cationic bishydrazide components **H** and **H-Cn** – the bisaldehyde component **A** alone was previously found unable to complex siRNA up to N/P 100.<sup>16</sup> The cationic peptide monomers were incubated overnight in sodium acetate buffer (25 mM, pH 5.5) in the presence of a fixed amount of siRNA. The results reveal that the non-amphiphilic DCP **A–H** complexes siRNA at N/P 20, which is comparable to our previous

### 3-components screening

Introducing amphiphilic bisaldehyde:




Introducing amphiphilic bishydrazide:



### 4-components screening

Introducing amphiphilic bisaldehyde & bishydrazide:



**Scheme 2** Description of the screening methodology where amphiphilic monomers are introduced either once at a time (3-components screening, top) or simultaneously (4-components screening, bottom). The colored spheres represent the different peptide-based monomers and the tail represents the aliphatic chain. The DCPs represented here are depicted, for simplicity, as block co-polymers but the amphiphilic monomers can also be statistically distributed within the DCPs. Instead of dynamic covalent co-polymers, it is also possible, in the case of the 4-components screening, to have selection and amplification of one DCP at the expense of other possibilities.



generation, while the starting building block **H** remained inactive up to N/P 150 (Fig. 2(A)).<sup>16</sup> Performing the 3-components screening by inserting the amphiphilic bishydrazides **H-Cn** resulted in the similar behaviour for the DCP **A-H-C6**: complexation was found to be now complete at N/P 10 whereas **H-C6** showed no sign of complexation up to N/P 150 (Fig. 2(B)). The enhancement of siRNA complexation of the amphiphilic DCP **A-H-C6** compared to the hydrophilic DCP **A-H** indicates an assistance of hydrophobic interactions during DCP and polyplex which may come from the formation of hydrophobic pockets where the non-covalent interactions governing polyplex formation are strengthened. Finally, moving to the longer C12 and C18 amphiphilic DCPs revealed that hydrophobic interactions become dominant in driving the assembly, reaching full complexation at N/P = 5 for DCPs **A-H-C12** and **A-H-C18**, but also for the amphiphilic components **H-C12** and **H-C18** (Fig. 2(C) and (D)).

The DCPs formed by **A + H** or **A-C12 + H-C12** were characterized by native MALDI-TOF mass spectrometry directly on the polyplexes formed at N/P 5. The results show the formation of cyclic and linear oligomers up to a degree of polymerization DP = 7–10. Since the detectability of oligomers by mass spectrometry decreases with length, it is also likely that longer oligomers do form. However, this result is consistent with our previous prediction<sup>17</sup> and with the findings of Aida and co-workers (Fig. 3, S33 and Table S1†).<sup>21</sup> Interestingly, the data confirm (i) the assistance of aliphatic chains – longer DPs are obtained for the amphiphilic DCPs – and (ii) the templating effect of siRNA – shorter oligomers being formed in the absence of siRNA.

### SiRNA delivery

Having demonstrated effective siRNA complexation, we then assessed the efficiency of these amphiphilic DCPs to deliver siRNA in cells by a luciferase activity knockdown assay in an MCF-7-Luc cancer cell line at a constant siRNA dose of 100 nM. The data reported here were normalized to the total number of living cells and thus reflect a true silencing activity (see ESI†). All experiments were initially performed at N/P 20 where siRNA




Fig. 2 SiRNA complexation, assessed by electrophoretic gel retardation assay, of DCPs versus amphiphilic monomer H: (A) **A-H**, (B) **A-H-C6**, (C) **A-H-C12**, and (D) **A-H-C18**. Concentration of each cationic peptide monomer = 66–400  $\mu$ M, depending on the N/P. Concentration of siRNA = 1.9  $\mu$ M.




Fig. 3 MALDI-TOF characterization of DCPs. Comparative analysis of siRNA-templated (**A-H**, top; **A-C12-H-C12**, middle) and non-templated DCPs (**A-C12-H-C12**, bottom). The coloured circles represent the cationic (**A** and **H** in light blue and light red, respectively) and amphiphilic (**A-C12** and **H-C12** in blue and red) peptide monomers.

complexation was found complete for all DCPs. Polyplexes were formulated at N/P 20 by incubating overnight a mixture of complementary monomers (100  $\mu$ M each) with siRNA (0.72  $\mu$ M) in sodium acetate buffer (25 mM, pH 5.5). In order to study the effect of hydrophobization on the silencing efficiency of siRNA, we performed a multi-component screening approach by introducing increasing proportions of amphiphilic monomers (e.g. **A-C12** and **H-C12**, Fig. 4). The starting point (0% amphiphilic monomers) shows no silencing effect – DCP **A-H** being therefore an ineffective vector despite its ability to effectively complex siRNA (*vide supra*). However, albeit the amphiphilic monomers **A-C12** and **H-C12** showed no activity alone (Fig. 4, hatched bars), the corresponding 4-component screening of amphiphilic DCPs ( $(100 - x)\% (\mathbf{A} + \mathbf{H}) + x\% (\mathbf{A-C12} + \mathbf{H-C12})$ ) reveals a dose-dependent inhibition of luciferase activity, reaching maximum efficacy for the DCPs **A-C12-H-C12** (Fig. 4,




Fig. 4 Luciferase activity knockdown and cell viability in MCF7-Luc cells of siRNA polyplexes formed from 3-components half-amphiphilic DCPs ( $\mathbf{A} + (100 - x)\% \mathbf{H} + x\% \mathbf{H-C12}$ : white bars/circles), ( $(100 - x)\% \mathbf{A} + x\% \mathbf{A-C12} + \mathbf{H}$ : cyan bars/circles) and 4-components amphiphilic DCPs ( $(100 - x)\% (\mathbf{A} + \mathbf{H}) + x\% (\mathbf{A-C12} + \mathbf{H-C12})$ : purple bars/circles), compared to siRNA alone (negative control), lipofectamine (positive control), **A-C12** alone, and **H-C12** alone. Luciferase activity was determined by luminescence measurements at 72 h after transfection. Data shows the mean  $\pm$  S.E.M. of conditions performed in triplicates. The experiments with DCPs were carried out at N/P 20 and those with the monomers **A-C12** and **H-C12** alone were therefore performed at N/P 10. SiRNA dose: 100 nM.



purple bars). This is remarkable given that the 3-component screening of half-amphiphilic DCPs (*i.e.*  $(A + (100 - x)\% H + x\% H\text{-C12})$  or  $((100 - x)\% A + x\% A\text{-C12} + H)$ ) did not show activity at all (Fig. 4, white and cyan bars, respectively). In other words, this means that efficient silencing of luciferase requires the introduction of both amphiphilic monomers. The successful delivery of siRNA was further confirmed by fluorescence microscopy using an Atto-488-labelled siRNA (Fig. S34†).

The cell viability was assessed by a colorimetric analysis using (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). While the monomers **A-C12** and **H-C12** alone showed no cytotoxicity, a significant decrease in cell viability to around 50% was observed when introducing more than 50% of amphiphilic monomers within the 4-component DCPs. Although the onset of cytotoxicity seems to be delayed compared to the silencing activity (see the 25% composition in Fig. 4), it is clear the two remain linked in this series of dynamic covalent lipopolyplexes. A LDH assay confirmed this trend (Fig. S35†), which suggests that the cytotoxicity of the dynamic covalent lipopolyplexes originate from a destabilisation of cellular membranes.

Since the excess of positive charges can account for cytotoxicity,<sup>37</sup> lower N/P were tested. In our case, both the cytotoxicity and the silencing activity were found to decrease at N/P 5 and 10 (Fig. 5). We also noticed that the insertion of more amphiphilic monomers is required when working at lower N/P. For instance, the onset of activity is observed at 25% amphiphilic monomers at N/P 20, but occurs at 50% of amphiphilic monomers at N/P 10 (Fig. 5). Similarly, testing lower siRNA doses (25 and 50 nM) showed the same trend but, for the first time, silencing activity was detected at a record low dose of 50 nM with DCP **A-C12-H-C12** (Fig. S36†).

We then tested the effect of chain length. The amphiphilic DCPs bearing the short C6 chain were found totally inactive (Fig. 6(A)). Even increasing the chain length to C10 did not elicit




Fig. 5 Luciferase activity knockdown and cell viability in MCF7-Luc cells of siRNA polyplexes formed from 4-components amphiphilic DCPs ( $(100 - x)\% (A + H) + x\% (A\text{-C12} + H\text{-C12})$ ) at different N/P, compared to siRNA alone (negative control), lipofectamine (positive control), **A-C12** alone, and **H-C12** alone. Luminescence readout was performed 72 h after transfection. Data show the mean  $\pm$  S.E.M. of conditions performed in triplicates. The experiments with the monomers **A-C12** and **H-C12** alone were performed at constant monomer : siRNA molar ratio, therefore at N/P 10. SiRNA dose: 100 nM.

any siRNA delivery activity (Fig. S37†). On the other hand, those with the C18 chain were found very active. Although the introduction of only 10% of C18-bearing amphiphilic monomers was sufficient to elicit a potent silencing activity with low associated cytotoxicity, the toxicity displayed by the monomers **A-C18** and **H-C18** discarded the selection of C18-bearing amphiphilic DCPs for further development (Fig. 6(B)).

Finally, to check whether the formation of DCP **A-C12-H-C12**, involving multiple acylhydrazone bonds, is indeed the underlying cause promoting siRNA complexation and delivery, we repeated the luciferase knockdown experiment in the presence of methoxyamine as a polymerization terminator. Indeed,




Fig. 6 Luciferase activity knockdown and cell viability in MCF7-Luc cells of siRNA polyplexes formed from 4-components amphiphilic DCPs with: (A) **A-C6** and **H-C6**; (B) **A-C18** and **H-C18**; (C) **A-C12** and **H-C12** in the presence of the polymerization terminator methoxyamine (2 to 40 equivalents with respect to bisaldehyde **A-C12**). Luminescence readout was performed 72 h after transfection. Data shows the mean  $\pm$  S.E.M. of conditions performed in triplicates. SiRNA dose: 100 nM.



by reacting with the bisaldehyde component to form stable oxime products, the action of methoxyamine prevents complementary monomers to associate into DCPs.<sup>10,38</sup> Interestingly, transfection was inhibited in the presence of methoxyamine, thus demonstrating that templated polymerization is required to trigger siRNA transfection and luciferase silencing (Fig. 6(C)).

### Physicochemical properties

The size of the polyplexes formed from the amphiphilic DCPs bearing the C12 chain was characterized by dynamic light scattering (DLS) and  $\zeta$  potential measurements.

When combined with siRNA at N/P 10, none of the monomers formed any detectable object by DLS (data not shown). Large nanoparticles (>800 nm) were detected for the half-amphiphilic DCPs A-C12-H or A-H-C12 (Table 1, entries 1 and 2), which may explain their inability to deliver siRNA in cells. However, no nanoparticles were detected in the absence of siRNA, showing again the critical role of this templating component. Interestingly, the polyplexes constructed at N/P 20 from the amphiphilic DCPs, composed of both C12 monomers, show smaller nanoparticle sizes – between 170 and 400 nm – and a decreasing polydispersity index (PDI down to 0.08) as the percentage of amphiphilic monomers increased (Table 1, entries 3–7). A correlation with the percentage of amphiphilic monomers is also observed looking at the surface potential, with  $\zeta$  potential values ranging from a minimum of  $-22$  mV to a maximum of  $+26$  mV (Table 1). This suggests that lipid moieties help the structuration of the assembly and promote positive charges on the surface of the assembly, which might also contribute to stabilize the particles by electrostatic repulsion.

Decreasing the N/P ratio from 20 down to 10 and 5 has a major impact, with nanoparticles increasing in size, being more polydisperse, and having decreased  $\zeta$  potential values

(Table 1, entries 8–17). The study of the polyplexes formed from the DCPs bearing the C6 and C18 chains revealed that the former generated larger nanoparticles of *ca.* 700 nm while the latter display sizes of 200–525 nm but more positive  $\zeta$  potential values of 15–56 mV (Table S6†).

The nanoparticles formed from the DCP A-C12-H-C12 were further characterized by transmission electron microscopy (TEM). The polyplexes at N/P 20 were formed at a higher concentration to improve the signal and obtain sufficient




Fig. 7 TEM images of the polyplex formed *in situ* from the DCP A-C12-H-C12 (top), and of the same system in the absence of siRNA (bottom). Dynamic covalent lipopolyplexes formation was performed overnight at a monomer concentration of 1 mM in sodium acetate buffer pH 5.5.

**Table 1** DLS analyses (size and polydispersity index) and  $\zeta$  potential measurements of DCP-based polyplexes. Polyplexes formation was performed *in situ* by mixing and incubating overnight siRNA with complementary monomers (composition indicated, 100  $\mu$ M for each monomer) in sodium acetate buffer (25 mM, pH 5.5). Further dilution in the same buffer to a final concentration of 100 nM siRNA was performed prior to the measurements

| Entry | Composition                             | N/P | x% C12 | Size (nm)     | PDI  | $\zeta$ potential (mV) |
|-------|---|-----|--------|---------------|------|------------------------|
| 1     | <b>A-C12 + H</b>                        | 20  | 50     | $1536 \pm 99$ | 0.22 | $-22 \pm 12$           |
| 2     | <b>A + H-C12</b>                        |     | 50     | $805 \pm 19$  | 0.32 | $-10 \pm 20$           |
| 3     | (100 – x)% (A + H) + x% (A-C12 + H-C12) | 20  | 0      | $332 \pm 126$ | 0.27 | $-2 \pm 5$             |
| 4     |   |     | 25     | $171 \pm 6$   | 0.44 | $-2 \pm 25$            |
| 5     |   |     | 50     | $324 \pm 54$  | 0.32 | $-5 \pm 11$            |
| 6     |   |     | 75     | $407 \pm 114$ | 0.19 | $+1 \pm 13$            |
| 7     |   |     | 100    | $195 \pm 47$  | 0.08 | $+26 \pm 9$            |
| 8     |   | 10  | 0      | n.d.          | —    | —                      |
| 9     |   |     | 25     | $333 \pm 88$  | 0.39 | —                      |
| 10    |   |     | 50     | $255 \pm 190$ | 0.27 | —                      |
| 11    |   |     | 75     | $977 \pm 60$  | 0.54 | —                      |
| 12    |   |     | 100    | $760 \pm 154$ | 0.25 | $-2 \pm 8$             |
| 13    |   | 5   | 0      | n.d.          | —    | —                      |
| 14    |   |     | 25     | n.d.          | —    | —                      |
| 15    |   |     | 50     | $1198 \pm 61$ | 0.63 | —                      |
| 16    |   |     | 75     | $1055 \pm 26$ | 0.44 | —                      |
| 17    |   |     | 100    | $2293 \pm 77$ | 0.51 | $-14 \pm 9$            |



contrast. The results show that these polyplexes appear as dense spherical nanoparticles cross-linked in larger aggregates (Fig. 7, top, and S38†), in stark contrast with the blurry and ill-defined structure observed with the exact same system but in the absence of siRNA (Fig. 7, bottom), thereby confirming again the prime role of the templating siRNA in directing the complex self-assembly pathway towards a more organized state. A particle size analysis revealed an average size for the individual spheres around 80 nm.

## Conclusions

We reported here the design and synthesis of new amphiphilic cationic peptide monomers for the siRNA-templated formation of DCPs and dynamic covalent lipopolyplexes. By screening multi-component libraries of amphiphilic DCPs, we successfully identified effective vectors of siRNA capable of eliciting a complete knockdown of luciferase at 100 nM dose, where our previous generation only achieved a 50% knockdown at 200 nM siRNA dose.<sup>16,17</sup> Significant siRNA activity was even detected at a 50 nM dose which sets a new record for DCP-based vectors. Moreover, by introducing these amphiphilic monomers, we also found that the physico-chemical properties of the resulting dynamic covalent lipopolyplexes are improved with the best hit (DCP A-C12-H-C12) leading to more defined nanoparticles (*ca.* 200 nm, PDI = 0.08) compared to the previous generation (*ca.* 400 nm, PDI = 0.4).<sup>16,17</sup> Overall, the results show that hydrophobization plays a major role in siRNA complexation, in the self-assembly of DCPs and dynamic covalent lipopolyplexes, and also boost the activity of siRNA delivery in cells, even though it comes with the critical challenge of dealing with associated cytotoxicity. This work contributes to the emerging exploration of (supra)molecular vectors which designs combine the best from lipoplexes and polyplexes.<sup>39</sup> We believe the simplicity and versatility of our *in situ* screening methodology which operates in mild conditions (simple mixing, room temperature, aqueous media) will enable further exploration of adaptive and evolutive multi-components libraries from which, through the templating action of nucleic acids and cell membranes, effective vectors can be selected and identified.<sup>14,40</sup>

## Data availability

The data supporting this article have been included as part of the ESI.†

## Author contributions

Investigation (J. G. C., P. T., S. D. P., Y. B.); resources (Y. B., L. L.); visualization (J. G. C., S. U.); writing – original draft (J. G. C., S. U.); writing – review & editing (all); supervision/validation (E. S., N. B., S. U.); conceptualization/methodology/funding acquisition/project administration (J. L. C., S. U.).

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

We thank Sandrine Sagan for her advices and valuable inputs, the ANR (SACSI, ANR-21-CE18-0039-01) and ARC foundation (ARCPJA2021060003831) for funding, Frank Godiard for the TEM analyses performed at the Microscopie Electronique et Analytique (MEA) facility, Université de Montpellier, the MS platform facility MS<sup>3</sup>U from Sorbonne University, and MRI (Montpellier RIO Imaging) platform for imaging facilities.

## References

- 1 S. Shtikalova, D. Deviatkin, S. Freund, A. Egorova and A. Kiselev, *Life*, 2023, **13**, 903.
- 2 J. A. Kulkarni, D. Witzigmann, S. B. Thomson, S. Chen, B. R. Leavitt, P. R. Cullis and R. van der Meel, *Nat. Nanotechnol.*, 2021, **16**, 630–643.
- 3 F. Guo, Y. Li, W. J. Yu, Y. L. Fu, J. Zhang and H. Q. Cao, *Mol. Pharmaceutics*, 2024, **21**, 2081–2096.
- 4 B. Hu, L. Zhong, Y. Weng, L. Peng, Y. Huang, Y. Zhao and X. J. Liang, *Signal Transduct. Target. Ther.*, 2020, **5**, 101.
- 5 M. Egli and M. Manoharan, *Nucleic Acids Res.*, 2023, **51**, 2529–2573.
- 6 K. Paunovska, D. Loughrey and J. E. Dahlman, *Nat. Rev. Genet.*, 2022, **23**, 265–280.
- 7 R. Kumar, C. F. Santa Chalarca, M. R. Bockman, C. Van Bruggen, C. J. Grimme, R. J. Dalal, M. G. Hanson, J. K. Hexum and T. M. Reineke, *Chem. Rev.*, 2021, **121**, 11527–11652.
- 8 U. Lächelt and E. Wagner, *Chem. Rev.*, 2015, **115**, 11043–11078.
- 9 For a recent example illustrating how improving the disassembly and release of nucleic acids can boost the activity, see: J. Asohan, H. H. Fakih, T. Das and H. F. Sleiman, *ACS Nano*, 2024, **18**, 3996–4007.
- 10 C. Bouillon, D. Paolantoni, J. C. Rote, Y. Bessin, L. W. Peterson, P. Dumy and S. Ulrich, *Chem.-Eur. J.*, 2014, **20**, 14705–14714.
- 11 C. Bouillon, Y. Bessin, F. Poncet, M. Gary-Bobo, P. Dumy, M. Barboiu, N. Bettache and S. Ulrich, *J. Mater. Chem. B*, 2018, **6**, 7239–7246.
- 12 For a recent review on self-assembly pathways involved in lipid nanoparticles for RNA delivery, see: V. Nele, V. Campani, S. A. Moosavian and G. De Rosa, *Adv. Drug Deliv. Rev.*, 2024, **208**, 115291.
- 13 S. Berger, U. Lächelt and E. Wagner, *Proc. Natl. Acad. Sci. U. S. A.*, 2024, **121**, e2307799120.
- 14 S. Ulrich, *Acc. Chem. Res.*, 2019, **52**, 510–519.
- 15 J. Garcia Coll and S. Ulrich, *ChemBioChem*, 2023, **24**, e202300333.
- 16 D. D. Su, L. M. A. Ali, M. Coste, N. Laroui, Y. Bessin, M. Barboiu, N. Bettache and S. Ulrich, *Chem.-Eur. J.*, 2023, **29**, e202202921.
- 17 N. Laroui, M. Coste, D. Su, L. M. A. Ali, Y. Bessin, M. Barboiu, M. Gary-Bobo, N. Bettache and S. Ulrich, *Angew. Chem., Int. Ed.*, 2021, **60**, 5783–5787.



18 B. D. Gonzalez, R. Lopez-Blanco, S. Parcero-Bouzas, N. Barreiro-Piñeiro, L. Garcia-Abuin and E. Fernandez-Megia, *J. Am. Chem. Soc.*, 2024, **146**, 17211–17219.

19 E. Bartolami, Y. Bessin, N. Bettache, M. Gary-Bobo, M. Garcia, P. Dumy and S. Ulrich, *Org. Biomol. Chem.*, 2015, **13**, 9427–9438.

20 N/P refers to the ratio of positive charges contained in the nitrogen-rich vector per negative charges in the siRNA.

21 P. K. Hashim, K. Okuro, S. Sasaki, Y. Hoashi and T. Aida, *J. Am. Chem. Soc.*, 2015, **137**, 15608–15611.

22 J. X. Chen, D. D. Zhu, B. P. Lian, K. J. Shi, P. Chen, Y. Li, W. Y. Lin, L. Ding, Q. L. Long, Y. Wang, E. Laurini, W. J. Lan, Y. Li, A. Tintaru, C. Y. Ju, C. Zhang, S. Pricl, J. Iovanna, X. X. Liu and L. Peng, *Proc. Natl. Acad. Sci. U. S. A.*, 2023, **120**, e2220787120.

23 Y. W. Dong, T. Z. Yu, L. Ding, E. Laurini, Y. Y. Huang, M. J. Zhang, Y. H. Weng, S. T. Lin, P. Chen, D. Marson, Y. F. Jiang, S. Giorgio, S. Pricl, X. X. Liu, P. Rocchi and L. Peng, *J. Am. Chem. Soc.*, 2018, **140**, 16264–16274.

24 X. X. Liu, J. H. Zhou, T. Z. Yu, C. Chen, Q. Cheng, K. Sengupta, Y. Y. Huang, H. T. Li, C. Liu, Y. Wang, P. Posocco, M. H. Wang, Q. Cui, S. Giorgio, M. Fermeglia, F. Q. Qu, S. Pricl, Y. H. Shi, Z. C. Liang, P. Rocchi, J. J. Rossi and L. Peng, *Angew. Chem., Int. Ed.*, 2014, **53**, 11822–11827.

25 A. K. Pearce and R. K. O'Reilly, *Biomacromolecules*, 2021, **22**, 4459–4469.

26 Z. H. Liu, Z. Y. Zhang, C. R. Zhou and Y. P. Jiao, *Prog. Polym. Sci.*, 2010, **35**, 1144–1162.

27 A. D. Araujo, H. N. Hoang, J. Lim, J. Y. W. Mak and D. P. Fairlie, *Angew. Chem., Int. Ed.*, 2022, **61**, e202203995.

28 A. Walrant, S. Cardon, F. Burlina and S. Sagan, *Acc. Chem. Res.*, 2017, **50**, 2968–2975.

29 C. Gehin, J. Montenegro, E.-K. Bang, A. Cajaraville, S. Takayama, H. Hirose, S. Futaki, S. Matile and H. Riezman, *J. Am. Chem. Soc.*, 2013, **135**, 9295–9298.

30 J. M. Priegue, D. N. Crisan, J. Martinez-Costas, J. R. Granja, F. Fernandez-Trillo and J. Montenegro, *Angew. Chem., Int. Ed.*, 2016, **55**, 7492–7495.

31 A. Walrant, A. Bauza, C. Girardet, I. D. Alves, S. Lecomte, F. Illien, S. Cardon, N. Chaianantakul, M. Pallerla, F. Burlina, A. Frontera and S. Sagan, *Biochim. Biophys. Acta, Biomembr.*, 2020, **1862**, 183098.

32 M. L. Jobin, M. Blanchet, S. Henry, S. Chaignepain, C. Manigand, S. Castano, S. Lecomte, F. Burlina, S. Sagan and I. D. Alves, *Biochim. Biophys. Acta, Biomembr.*, 2015, **1848**, 593–602.

33 C. Bechara, M. Pallerla, Y. Zaltsman, F. Burlina, I. D. Alves, O. Lequin and S. Sagan, *FASEB J.*, 2013, **27**, 738–749.

34 H. A. Rydberg, M. Matson, H. L. Åmand, E. K. Esbjörner and B. Nordén, *Biochemistry*, 2012, **51**, 5531–5539.

35 K. A. Whitehead, J. R. Dorkin, A. J. Vegas, P. H. Chang, O. Veiseh, J. Matthews, O. S. Fenton, Y. L. Zhang, K. T. Olejnik, V. Yesilyurt, D. L. Chen, S. Barros, B. Klebanov, T. Novobrantseva, R. Langer and D. G. Anderson, *Nat. Commun.*, 2014, **5**, 4277.

36 Y. Z. Dong, K. T. Love, J. R. Dorkin, S. Sirirungruang, Y. L. Zhang, D. L. Chen, R. L. Bogorad, H. Yin, Y. Chen, A. J. Vegas, C. A. Alabi, G. Sahay, K. T. Olejnik, W. H. Wang, A. Schroeder, A. K. R. Lytton-Jean, D. J. Siegwart, A. Akinc, C. Barnes, S. A. Barros, M. Carioto, K. Fitzgerald, J. Hettinger, V. Kumar, T. I. Novobrantseva, J. N. Qin, W. Querbes, V. Koteliansky, R. Langer and D. G. Anderson, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 3955–3960.

37 R. Kedmi, N. Ben-Arie and D. Peer, *Biomaterials*, 2010, **31**, 6867–6875.

38 E. Bartolami, Y. Bessin, V. Gervais, P. Dumy and S. Ulrich, *Angew. Chem., Int. Ed.*, 2015, **54**, 10183–10187.

39 S. Thalmayr, M. Grau, L. Peng, J. Poehmerer, U. Wilk, P. Folda, M. Yazdi, E. Weidinger, T. Burghardt, M. Hoehn, E. Wagner and S. Berger, *Adv. Mater.*, 2023, **35**, 2211105.

40 F. Freitag and E. Wagner, *Adv. Drug Delivery Rev.*, 2021, **168**, 30–54.

